Achieve Life Sciences enters $150M ATM offering with Jefferies for cytisinicline funding

ACHIEVE LIFE SCIENCES, INC.

Entered Open Market Sale Agreement with Jefferies LLC for up to $150M in common stock ATM sales.
Jefferies receives up to 3.0% commission on gross proceeds; company may suspend or terminate at any time.
Proceeds to fund commercialization of cytisinicline and Phase 3 trial for e-cigarette cessation.
Shares sold under existing Form S-3 registration statement filed Jan 23, 2026; no obligation to sell.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.